As AI becomes embedded in life sciences R&D, companies face a critical strategic question: where does the real intellectual property value lie in their AI-enabled technologies? The answer increasingly points beyond the AI model itself to the complete technology architecture—encompassing data provenance, workflow integration, and the technical interfaces between software, biology, and physical processes.